← Back to news
July 23, 2026
FDA Advisory Committee Votes to Allow Specialized Pharmacies to Produce Controversial Peptides
- The FDA's advisory committee voted 8-6 to recommend easing restrictions on several peptides, including BPC-157, TB-500, and KPV, allowing specialized pharmacies to produce them.
- Despite warnings from health experts about safety and efficacy, the recommendation could lead to increased availability of these peptides for prescription.
- Health Secretary Robert F. Kennedy Jr. supports the easing of restrictions and aims to reverse previous regulations imposed during the Biden administration.
- The FDA is not required to follow the panel's recommendations, but it typically does.
5 Sources
- A Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s AgendaJul 23, 2026 at 9:04 AM · NYT
- FDA considers green-lighting unproven peptide injections boosted by RFK Jr as scientists issue warningsJul 23, 2026 at 3:45 PM · Independent
- US health panel recommends easing restrictions on controversial peptidesJul 23, 2026 at 10:45 PM · The Guardian
- FDA panel votes to loosen restrictions for controversial peptidesJul 23, 2026 at 10:55 PM · BBC
- FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientistsJul 23, 2026 at 11:38 PM · The Hill